405 related articles for article (PubMed ID: 9458091)
1. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.
Haaz MC; Rivory L; Riché C; Vernillet L; Robert J
Cancer Res; 1998 Feb; 58(3):468-72. PubMed ID: 9458091
[TBL] [Abstract][Full Text] [Related]
2. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes.
Haaz MC; Riché C; Rivory LP; Robert J
Drug Metab Dispos; 1998 Aug; 26(8):769-74. PubMed ID: 9698291
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos A; Zanetta S; Cresteil T; Deroussent A; Pein F; Raymond E; Vernillet L; Risse ML; Boige V; Gouyette A; Vassal G
Clin Cancer Res; 2000 May; 6(5):2012-20. PubMed ID: 10815927
[TBL] [Abstract][Full Text] [Related]
4. Determination of drug interactions occurring with the metabolic pathways of irinotecan.
Charasson V; Haaz MC; Robert J
Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202
[TBL] [Abstract][Full Text] [Related]
5. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4.
Sai K; Kaniwa N; Ozawa S; Sawada JI
Drug Metab Dispos; 2001 Nov; 29(11):1505-13. PubMed ID: 11602529
[TBL] [Abstract][Full Text] [Related]
6. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE
Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296
[TBL] [Abstract][Full Text] [Related]
7. Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide.
Zhang L; Fitzloff JF; Engel LC; Cook CS
Xenobiotica; 2001 Feb; 31(2):73-83. PubMed ID: 11407536
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
9. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
10. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
[TBL] [Abstract][Full Text] [Related]
11. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
[TBL] [Abstract][Full Text] [Related]
12. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
Rodrigues AD; Roberts EM; Mulford DJ; Yao Y; Ouellet D
Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603
[TBL] [Abstract][Full Text] [Related]
13. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Martínez C; García-Martín E; Pizarro RM; García-Gamito FJ; Agúndez JA
Br J Cancer; 2002 Sep; 87(6):681-6. PubMed ID: 12237780
[TBL] [Abstract][Full Text] [Related]
14. Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes.
Harrell AW; Wheeler SM; Pennick M; Clarke SE; Chenery RJ
Drug Metab Dispos; 1993; 21(1):18-23. PubMed ID: 8095215
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
Casabar RC; Wallace AD; Hodgson E; Rose RL
Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053
[TBL] [Abstract][Full Text] [Related]
16. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.
Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R
J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214
[TBL] [Abstract][Full Text] [Related]
17. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
Rivory LP; Riou JF; Haaz MC; Sable S; Vuilhorgne M; Commerçon A; Pond SM; Robert J
Cancer Res; 1996 Aug; 56(16):3689-94. PubMed ID: 8706009
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
19. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine.
Raeissi SD; Guo Z; Dobson GL; Artursson P; Hidalgo IJ
Pharm Res; 1997 Aug; 14(8):1019-25. PubMed ID: 9279883
[TBL] [Abstract][Full Text] [Related]
20. The xenobiotic inhibitor profile of cytochrome P4502C8.
Ong CE; Coulter S; Birkett DJ; Bhasker CR; Miners JO
Br J Clin Pharmacol; 2000 Dec; 50(6):573-80. PubMed ID: 11136296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
